Answers are grounded in this paper and cite their sources.
In a phase III study, Merck's new V503 human papillomavirus (HPV) vaccine prevented 97% of high-grade, precancerous vaginal, vulvar, and cervical disease caused by HPV types 31, 33, 45, 52, and 58. The new vaccine also generated immune responses to HPV types 6, 11, 16, and 18 that were as good as or better than those generated by the company's Gardasil vaccine.
No takes yet. Share an insight, caveat, or question.
A 2013 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: